ArticleBioresources and bioprocessing2021
α-Farnesene production from lipid by engineered Yarrowia lipolytica.
Article in Bioresources and bioprocessing, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 34 citations in OpenAlex.
- Engineering ofACS omega · 2026Article
- EngineeringSynthetic and systems biotechnology · 2025Article
- A functional and applied perspective of Vitreoscilla hemoglobin: from oxygen carriage to biotechnological innovation.Biotechnology letters · 2025Review
- Sustainable biosynthesis of squalene from waste cooking oil by the yeastMetabolic engineering communications · 2024Article
- Revealing the Mechanisms of Enhanced β-Farnesene Production inInternational journal of molecular sciences · 2023Article
- Cofactor Engineering for Efficient Production of α-Farnesene by Rational Modification of NADPH and ATP Regeneration Pathway inInternational journal of molecular sciences · 2023Article
- Integrated pathway engineering and transcriptome analysis for improved astaxanthin biosynthesis inSynthetic and systems biotechnology · 2022Article
- Engineering ofMetabolic engineering communications · 2022Review
- Engineering Yarrowia lipolytica for the sustainable production of β-farnesene from waste oil feedstock.Biotechnology for biofuels and bioproducts · 2022Article
- Recent advances in construction and regulation of yeast cell factories.World journal of microbiology & biotechnology · 2022Review
- Toward improved terpenoids biosynthesis: strategies to enhance the capabilities of cell factories.Bioresources and bioprocessing · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Producing high value-added products from waste lipid feedstock by microbial cell factory has great advantages to minimize the pollution as well as improve the economic value of wasted oils and fats. Yarrowia lipolytica is a non-conventional oleaginous yeast and can grow on a variety of hydrophobic substrates. In this study, we explored its ability to synthesize α-farnesene, an important sesquiterpene, using lipid feedstock. Based on the α-farnesene production strain, we constructed previously, we identified that Erg12 was the key limiting factor to further increase the α-farnesene production. The α-farnesene production was improved by 35.8% through increasing the copy number of ERG12 and FSERG20 on oleic acid substrate. Expression of heterologous VHb further improved α-farnesene production by 12.7%. Combining metabolic engineering with the optimization of fermentation conditions, the α-farnesene titer and yield reached 10.2 g/L and 0.1 g/g oleic acid, respectively, in fed-batch cultivation. The α-farnesene synthesis ability on waste cooking oil and other edible oils were also explored. Compared with using glucose as carbon source, using lipid substrates obtained higher α-farnesene yield and titer, but lower by-products accumulation, demonstrating the advantage of Y. lipolytica to synthesize high value-added products using lipid feedstock.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.